APP Pharma gets FDA nod for generic cancer drug
Feb 27 (Reuters) - APP Pharmaceuticals Inc APPX.O said the U.S. Food and Drug Administration approved its generic version of Pfizer Inc's (PFE.N: Quotazione) Camptosar injection to treat cancer of the large intestine and rectum.
APP said it has immediately begun marketing and shipping the generic Irinotecan Hydrochloride Injection.
The maker of injectable pharmaceutical products said sales of Camptosar in the United States were about $556 million in 2007, citing IMS data. (Reporting by Anant Vijay Kala in Bangalore, Editing by Himani Sarkar)
© Thomson Reuters 2017 Tutti i diritti assegna a Reuters.